Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Novartis, CMS Continue To Talk On Visudyne Macular Degeneration Coverage

  • News

Executive Summary

Novartis and the Centers for Medicare & Medicaid Services will be meeting right up until the deadline for expanded coverage for Novartis/QLT's Visudyne

You may also be interested in...



QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied

QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004

QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied

QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004

Novartis/QLT Visudyne Medicare Coverage Expansion Awaits More Data

The Centers for Medicare & Medicaid Services will ask for unpublished information from a peer-reviewed study of Novartis/QLT's Visudyne (verteporfin) for age-related macular degeneration before it expands coverage to off-label indications

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS039503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By